Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prevention of HIV-1 transmission at mucosal surfaces will likely require durable pre-existing mucosal anti-HIV-1 antibodies (Abs). Defining the ontogeny, specificities and potentially protective nature of the initial mucosal virus-specific B-cell response will be critical for understanding how to induce protective Ab responses by vaccination. Genital fluids from patients within the earliest stages of acute HIV-1 infection (Fiebig I-VI) were examined for multiple anti-HIV specificities. Gp41 (but not gp120) Env immunoglobulin (Ig)A Abs were frequently elicited in both plasma and mucosal fluids within the first weeks of transmission. However, shortly after induction, these initial mucosal gp41 Env IgA Abs rapidly declined with a t(½) of ∼2.7 days. B-cell-activating factor belonging to the TNF family (BAFF) was elevated immediately preceding the appearance of gp41 Abs, likely contributing to an initial T-independent Ab response. HIV-1 transmission frequently elicits mucosal HIV-1 envelope-specific IgA responses targeted to gp41 that have a short half-life.

More information Original publication

DOI

10.1038/mi.2012.107

Type

Journal article

Publication Date

2013-07-01T00:00:00+00:00

Volume

6

Pages

692 - 703

Total pages

11

Addresses

D, u, k, e, , H, u, m, a, n, , V, a, c, c, i, n, e, , I, n, s, t, i, t, u, t, e, ,, , D, u, k, e, , U, n, i, v, e, r, s, i, t, y, ,, , D, u, r, h, a, m, ,, , N, o, r, t, h, , C, a, r, o, l, i, n, a, ,, , U, S, A, .

Keywords

B-Lymphocytes, Humans, HIV-1, HIV Infections, Immunoglobulin A, Immunoglobulin G, HIV Envelope Protein gp41, Lymphocyte Activation, Antibody Specificity, Immunity, Mucosal, Time Factors, Female, Male, B-Cell Activating Factor